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Abstract
Background: Since the inception of the National Institute for Health and Clinical Excellence (NICE) in England,
there have been questions about the empirical basis for the cost-per-QALY threshold used by NICE and whether
QALYs gained by different beneficiaries of health care should be weighted equally. The Social Value of a QALY
(SVQ) project, reported in this paper, was commissioned to address these two questions. The results of SVQ were
released during a time of considerable debate about the NICE threshold, and authors with differing perspectives
have drawn on the SVQ results to support their cases. As these discussions continue, and given the selective use of
results by those involved, it is important, therefore, not only to present a summary overview of SVQ, but also for
those who conducted the research to contribute to the debate as to its implications for NICE.
Discussion: The issue of the threshold was addressed in two ways: first, by combining, via a set of models, the
current UK Value of a Prevented Fatality (used in transport policy) with data on fatality age, life expectancy and
age-related quality of life; and, second, via a survey designed to test the feasibility of combining respondents’
answers to willingness to pay and health state utility questions to arrive at values of a QALY. Modelling resulted in
values of £10,000-£70,000 per QALY. Via survey research, most methods of aggregating the data resulted in values
of a QALY of £18,000-£40,000, although others resulted in implausibly high values. An additional survey, addressing
the issue of weighting QALYs, used two methods, one indicating that QALYs should not be weighted and the
other that greater weight could be given to QALYs gained by some groups.
Summary: Although we conducted only a feasibility study and a modelling exercise, neither present compelling
evidence for moving the NICE threshold up or down. Some preliminary evidence would indicate it could be
moved up for some types of QALY and down for others. While many members of the public appear to be open to
the possibility of using somewhat different QALY weights for different groups of beneficiaries, we do not yet have
any secure evidence base for introducing such a system.
Background
The concept of the value of a quality adjusted life year
(QALY) is not new to health economics [1], but has
reached prominence in policy and in empirical research
due to the creation of national-level health technology
assessment agencies [2-5]. When assessing particular
interventions in terms of health gains against the costs
of provision, such agencies must, in effect, put a
monetary value on those health gains. In the context of
England, where the National Institute for Health and
Clinical Excellence (NICE) uses the QALY as its health
metric, NICE must decide what value(s) of a QALY to
use.
Since the inception of NICE, the threshold value of a
QALY has been £20-30,000 [6]. Interventions with a
cost per QALY above this range are less likely to be
recommended by NICE for adoption by the rest of the
NHS [7,8]. The threshold was based on best guesses of
experts at the inception of NICE6 and has been subject
to criticism since the UK House of Commons Health
Committee review of NICE in 2001-2 [9]. The criticism
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at that time centred on the lack of an empirical basis for
the threshold. More recently, pressure has been placed
on NICE to raise the threshold, as exemplified in the
case of life-extending drugs for people in the terminal
phase of cancer [10,11], and to lower it, based on forth-
coming fiscal pressures and views of primary care trusts
(PCTs) that NICE guidance is not affordable [12].
Indeed, arguments for and against raising the threshold
were debated in a recent head-to-head in the BMJ
[13,14].
Partly in response to such criticism, NICE co-funded
two research projects in 2004. One of these, the Social
Value of a QALY (SVQ) project, was conducted by the
authors of this paper. The results of SVQ have recently
been published [15,16], and used in some quarters to
put further upward pressure on the threshold
[10,11,13,17]. However, use of the results in such report-
ing has been selective. It is important that a summary
overview of the project is presented. Also, the views of
those who conducted the research as to its implications
for the NICE threshold have not been expressed before.
The purposes of this paper are to provide such a sum-
mary and interpretation for policy. Of course, in making
a summary and drawing interpretations, it is important
to recognise that, as with all such valuation approaches,
the methods used are controversial. The reader is able
to draw conclusions on such issues from reading more
in-depth reports of these methods in other peer-
reviewed publications [15,16]. Nevertheless, returning to
the main point of this paper, it will be seen that the
issue of whether to raise the value-of-a-QALY bar or
bar the raise is somewhat more complex than discussed
to date and that both sides in the debate are right, but
also wrong.
Discussion
The SVQ project
There are different ways of seeking a value of a QALY.
Valuable information has been generated, for example,
in analysis of the affordability and cost of generating a
QALY at the level of PCTs, given their pre-determined
budgets [18,19]. SVQ consisted of three related strands,
each based on eliciting values from members of the gen-
eral public. The first strand involved modelling the
monetary value of a QALY from the willingness-to-pay
(WTP)-based value of preventing a statistical fatality
(VPF) that the UK Department for Transport (DfT) and
other public sector agencies apply to life-saving projects.
This value is derived from asking representative samples
of the public about their WTP for safety improvements.
These improvements are characterised as reducing the
risk of death for any individual by small amounts in the
forthcoming time period (e.g. the coming year). Across
a population, a small number of actual lives will be
saved. In simple terms, dividing aggregate WTP of the
population by this small number of lives saved gives us
the VPF. With WTP values being elicited from a cross-
section of the population it can be argued that the
resulting VPF (or value of a QALY, if that is the focus
of interest) is reflective of society’s overall budget con-
straint. An important ethical standpoint is that the
resulting ‘average’ value is applied to each member of
society regardless of income. Indeed, public sector agen-
cies that employ WTP-based values (such as the DfT
and the Health and Safety Executive in the UK) invari-
ably do apply the same value, based on the population
average, to all income groups.
A simplified version of the method of transforming
the VPF into a value of a QALY is as follows:
A straightforward way to compute the value of a
QALY is to start with the well-established roads
VPF for the UK. For example, if we take a represen-
tative death avoided as being that of a person aged
35, assume that the VPF is £1.4 m (or £1.4 × 106)
and that the person concerned would have lived for
another 40 years, a rough calculation of the value of
a life year gained by that person would be as follows:
V
35
£1.4 10
=
=
× 6
40
000£ ,
Conveniently, V is close to the value of a QALY
espoused by Rawlins and Culyer in their 2004 British
Medical Journal paper [6]. However, if one were to
assume that not all of the 40 years gained would be
spent in full health (especially later years) and a dis-
count rate applied, the denominator would fall, thus
raising the value of a QALY above £35,000. For
example, if the discount rate was taken to be 3.5%
then the annualised sum that would have a dis-
counted present value of £1.4 m over 40 years would
be £77,300.
However, the value resulting from this would reflect a
particular QALY type. By QALY-type, we mean that
QALYs can be generated in at least two ways; these
being by adding years to life or by enhancing the quality
of remaining life years without extending life. The for-
mer can be further subdivided into avoiding immediate
threats to life or adding years to the end of one’s life.
The procedure outlined above reflects the first of these,
although a more-sophisticated approach, still using the
VPF was also used to model the value of a QALY aris-
ing from life extension as opposed to life saving [15].
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Similar WTP procedures were also used by DfT to
derive the VSI, or value of a serious injury prevented
[20], from which a value of a quality-of-life-enhancing
QALY can be derived [15], summarised as follows:
Each serious injury was broken down into 3 phases;
in hospital effect (valued at 0.69 or 0.16 on the
EQ-5D tariff, depending on severity of injury and
generally modelled as lasting for one month), initial
after-effects (generally for two months and valued at
0.76) and longer-term effects (for remaining life and
valued at either 0.76 or 0.3, again depending on
severity). Assuming that any given injury would
occur at the mean age of the UK population, with
26 expected remaining QALYS, we calculated an
overall total QALY loss for each scenario. We then
divided the VSI of £150,000 by the total QALY loss
for each scenario and computed a weighted average
based on probability of each scenario occurring.
Thus, values for all three QALY types could be
explored within the research.
Note that, beyond this, SVQ did not look at the value
attached to QALY gains from treating specific diseases.
This is due to a more generic rather than disease-speci-
fic approach to economic evaluation being the tradition
in UK health economics and decision making.
The second strand of SVQ assessed the feasibility of
obtaining an estimate of the monetary value of a QALY
by presenting members of the public with appropriately
framed valuation questions in a survey. Example health
states are as follows:
Stomach: 3 months
Initially you will have severe stomach pains, diar-
rhoea, vomiting and fever for 7 days, severe enough
to interfere with most of your usual activities.
Things then improve, but for up to one year from
initial onset you will suffer an episode of stomach
discomfort and sickness every couple of weeks, with
each episode lasting for 2-3 days. These episodes are
not so severe but may interfere with some of your
usual activities.
(Half of the respondents were given stomach health
state descriptions of 3 months, 12 months and life-
time durations.)
Head: 3 months
You will have episodes of throbbing pain across the
front of your head and you will feel sick and may
occasionally be sick. You will feel like you want to
lie still in a darkened room.
During the next three months you will suffer an epi-
sode of head pain and sickness every couple of
weeks, with each episode lasting between 8 hours
and two days. These episodes will interfere with
many of your usual activities. After three months
you return to your current health with no further
effects from this illness.
(The other half of the respondents were given head
health state descriptions of 3 months, 12 months and
lifetime durations.)
An example question to illustrate how changes in
quality of life and WTP were estimated and combined
was as follows:
The value of a QALY is derived via a ‘chaining’ proce-
dure. In the initial part of the chain, the respondent is
asked about whether s/he would be prepared to pay
anything to avoid being in this state, and, if so, what
is the maximum amount s/he is willing to pay.
In the second part of the chain, the respondent
would be asked a ‘standard gamble’ question invol-
ving a choice between two options. In the standard
way of deriving a QALY index, one option would
leave the respondent in the stomach/head condition
for certain for the remainder of his/her life whilst
the other option would involve a gamble with vary-
ing probabilities of a better or worse outcome. ‘Bet-
ter’ usually means a return to full health for the rest
of one’s life, whilst worse is usually characterised as
immediate death. Visual procedures are used to
guide the respondent through the process, and the
index is derived from the point at which the respon-
dent feels it is difficult to choose between the out-
come for certain and the gamble.
Let us assume that, for one respondent, the prob-
ability at which s/he finds it difficult to choose
between the head condition for certain and taking
the gamble is 0.95 and that his/her WTP to avoid a
year in the stomach condition was £1000. Dividing
£1000 by 0.05 (which comes from subtracting 0.95
from 1) would give a value of a QALY for that per-
son of £20,000. This can be done across several indi-
viduals to arrive at an average value of a QALY for a
population.
For either head or stomach conditions, each respon-
dent was asked two WTP questions (to avoid the
three-month state and the 12-month state) and
three standard gamble questions (3 months for cer-
tain vs a gamble with outcomes of return to current
health or 12 months in the state; 12 months for cer-
tain vs a gamble with outcome of return to current
health or rest of life in the state; and rest if life for
certain vs gamble with outcomes of current health
or immediate death). In fact slightly more WTP and
standard gamble questions were asked of each
respondent, but these are not relevant to this paper.
Donaldson et al. BMC Health Services Research 2011, 11:8
http://www.biomedcentral.com/1472-6963/11/8
Page 3 of 8
From this, it can be seen that any individual respon-
dent would be faced with a set of WTP and standard
gamble questions, the two sets then being combined in
different ways to arrive at values of a QALY. Respon-
dents could have been asked time trade-off questions
instead of standard gambles, our rationale for the latter
simply being that it comes from the same theoretical
‘stable’ as WTP. On the other hand, given that the
QALY tariff used by NICE is based on time trade-off
(using 10-year time horizons) it is not necessarily the
case that direct comparison between the value of a
QALY derived from SVQ and NICE’s valuation of a
QALY can be made. Also, rather than combine WTP
values with a pre-existing tariff (such as that which
exists for the EQ-5D quality of life system), we wanted
our own respondents to provide health state utility
values that could be combined with their own WTP
values for purposes of internal consistency. Eliciting
WTP from our sample and then combining these with
EQ-5D values from a different population would also
have been problematic. Of course, standard gambles are
known to have problems with lack of sensitivity [21],
and WTP methods, as with other valuation methods,
have been robustly criticised and defended, and are thus
controversial [22]. However, the aim of this part of SVQ
was to test the feasibility and robustness of the elicita-
tion methods; and, rather than conduct a full-scale
national sample survey, the sample was restricted to 400
people which was not representative of the population.
The third strand aimed to investigate the extent to
which members of the public consider that there may
be legitimate grounds for distinguishing between the
social value to be accorded to QALYs gained by differ-
ent types of patient. It should be noted here that, rather
than being about the personal (or individual) value of a
QALY, as in strands 1 and 2, strand 3 is about valuing
QALYs in others. For example, should a particular
QALY gain delivered to someone currently in very poor
health be weighted differently from the same number of
QALYs delivered to people whose current health state is
not nearly so bad? Should a paediatric QALY be
weighted differently from a geriatric QALY? As in the
disability adjusted life year literature, should gains to the
very young and older people be given less weight than
those of productive age? [23] Descriptions of the two
main types of question used in SVQ to examine these
issues are as follows:
Person trade-off (PTO)
Using this method, respondents in SVQ were asked
how many people of certain characteristics (e.g. in
terms of stage of life and/or severity of condition)
and achieving some sort of QALY gain (usually
four QALYs) would be judged equivalent to, say,
100 people with different degrees of the same char-
acteristics who might also achieve such a gain. If a
number less than 100 is given in response that
would mean that the gains to the former group are
valued higher than to the latter. A series of such
questions can be asked to try to establish the exact
person trade off (where the respondent cannot
choose between the two options). These numbers
can then be used to establish what the ‘weights’ for
different scenarios presented would be for one indi-
vidual and can be aggregated to establish what the
weights might be at the population level.
Discrete choice experiments (DCEs)
Using this method in SVQ, respondents were pre-
sented with a series of choices between scenarios.
These scenarios looked similar to those used in the
PTO with choice made on the basis of stage of life
and severity, except that (a) the size of the health
gain was also allowed to vary across the scenarios in
any one choice set and (b) the respondent merely
chose one scenario in preference to the other, and
did not use numbers of people to weight the scenar-
ios. Again, with each respondent making a series of
such choices, statistical procedures can be employed
to arrive at a set of weights across a population
sample.
(Each respondent answered 6 PTO and 8 DCE ques-
tions. To aid the process, these questions were pre-
sented in a diagrammatic form in a computer-
assisted version of the questionnaire. This procedure
was developed in over a year of developmental and
piloting work prior to the main survey.)
The person trade-off method was based on the earlier
work on Nord [24,25] and the discrete choice methods
were new to this area of application.
QALY-types
Table 1 gives a typical set of values of a QALY that have
arisen from the modelling. It would seem that different
‘QALY-types’ would imply different values. Based on
WTP to reduce the risks of life-threatening events,
values close to £70,000 per QALY were produced, as
compared to values around £35,000 for a life-extending
QALY. Estimating gains from improvements in quality
Table 1 Values of a QALY via alternative calculations
from modelling based on VPF and VSI
Basic modelling approach Value of a QALY (£)
Life-saving £70,000
Life-extending £35,000
Quality-of-life-enhancing £10,000
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of life, with no increase in number of remaining years,
produced a lower value of about £10,000 per QALY.
Nevertheless, it is worth noting that the above results
imply that the threshold could be raised for life-saving
QALYs. One note of caution, however, involves reflect-
ing on what might be meant by a life-saving QALY
being valued at seven times that of a quality-of-life-
enhancing QALY. Although not calculated like this, it
might be reasonable to assume that the ‘average’ utility
score across the profiles of serious injuries were, say,
0.6. This would imply that WTP to avoid a fatality
would be just over 11 times that for the serious injury
(i.e. 70,000/10,000 × 1.0/0.6). This, along with the
results in Table 1 therefore, presents a hypothesis that
requires further testing. (It is worth noting here that the
issue of WTP for QALY types was not explored directly
in survey work in SVQ but has been incorporated into
subsequent surveys on the ‘European value of a QALY’ -
see the EuroVaQ website at http://research.ncl.ac.uk/
eurovaq/). It is also worth noting that the VPF itself is
just over nine times the value of the VSI. That there is
no single value of a QALY is in line with other pub-
lished views [26], the lowest value also being reflective
of earlier published studies which looked at the value of
QALY gains arising from quality-of-life enhancement
only [3,27].
But where does this leave particular groups, such as
those with very low remaining life expectancy who will
die prematurely anyway (such as cancer patients “close
to death”)? SVQ does not have a specific answer to this,
as life-saving QALY values arising from the project are
based on the assumption that those saved will go on to
live a full and healthy life. The analytical framework
applied in the first strand of SVQ (and developed
further in a related study of nuclear risks commissioned
by the Health and Safety Executive [28]) suggests that
there might be a case for higher values to be assigned
to QALYs delivered to those categories of patient. How-
ever, this case would be based on the values of people
close to death only. Drawing parallels with the earlier
argument (in the Methods section) regarding income
groups, this would contravene an ethical standpoint sup-
porting the application of an average value from a cross-
section of the population to all members of that
population.
Results of fieldwork investigating the value(s) assigned to
a QALY
The second strand of the study suggested that it is feasi-
ble to conduct a survey to elicit monetary values for a
QALY from a representative sample of the public so
long as the procedure is broken down into manageable
steps and is carried out on a face-to-face basis by well-
trained interviewers. However, it also became apparent
that the mean estimates produced by such questions are
particularly prone to the influence of “outlier responses”
and that great care is therefore required in the selection
of central-tendency measures. The most common exam-
ple of an outlier was that many people were willing to
take only very small risks of a more adverse outcome to
avoid the stomach and head health states in the stan-
dard gamble questions, or were even not willing to gam-
ble at all. As well as such floor effects, respondents may
also have a WTP ceiling (or budget constraint), an
amount they express whether for a small or large per-
ceived gain. Thus, when WTP values and health state
utilities are combined in such circumstances, the
implied WTP per QALY for such individuals can be so
high as to lead to an implausible population average
WTP per QALY across the whole sample. This was
indeed the case in SVQ, with the value running into
several millions of pounds!
Other ways of managing the data, therefore, are dis-
played in Table 2. Rather than computing a ratio of
WTP/QALY loss for each individual and then taking a
mean, the first two calculations take the mean WTP,
the mean QALY loss and then compute the ratio. This
is done for each of the stomach and head scenarios. The
third calculation takes a ratio of medians. So, for exam-
ple, using median stated WTP to avoid the certainty of
a 12-month period of illness, the figures suggest a value
for a QALY in the region of £20,000-£40,000.
Finally, in the third strand of the SVQ study, aimed at
quantifying the effect of age and health status on the
public’s valuation of QALY gains, as is often the case
where two different approaches are used, each produced
somewhat different results. This discrepancy between
the results of the two approaches reflects the differing
results based on similar approaches that is emerging
over time in the literature [29-32], and will almost cer-
tainly require further research if a definitive resolution
is to be established. Nevertheless, one of the approaches
appeared to provide grounds for giving significantly
greater weight to the value of QALYs gained by younger
adults suffering from fairly severe health impairments as
compared with very small children or elderly people,
especially if their impairments were not very severe.
Further research
Given the degree of variability in values reported, the
issue of differential values for QALY types requires
urgent attention. Three issues are particularly worthy of
this. In chaining the values derived from standard gam-
ble and WTP questions there appears to be a methodo-
logical problem in identifying health states which are
serious enough to encourage more respondents to trade
them (against risks of death and full health) in standard
gambles, but which are not so serious that paying for
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their avoidance is perceived as unaffordable in WTP
questions.
The second issue is that of the value of ‘QALY types’.
Initial evidence from the first strand of the research
reported indicates that different types of QALYs may
have different values. The results in Table 1 indicating
this require further research in order to be confirmed or
refuted. Linked to this, a major policy gap also seems to
be that of providing valuations to be attached to short-
term QALY gains for those in terminal phases of illness.
Notably, NICE has raised the threshold for such condi-
tions; although this would be expressed by them as a
weighting of the single £20,000-£30,000 threshold rather
than having changed the threshold as such.
Thirdly, at least some of the study’s findings suggest
that differential weighting of QALY gains by characteris-
tics of beneficiaries is a possibility deserving further
consideration. In terms of research, the two approaches
used in SVQ (discrete choice and PTO) are worthy of
refinement and comparison. Furthermore, although not
explicitly researched in SVQ, the concern of people for
ensuring the right to realise health potential [33,34]
could be incorporated into such future work. This con-
cern is based on the egalitarian view that people be
allowed to realise their potential for health and that
rights to access care should depend less on maximising
gains in quality or length of life. Evidence that this is of
concern to the public has been found in several coun-
tries [33-36], including the UK [37], and would also
explain somewhat the position of other HTA agencies,
such as the Institute for Quality and Economizing
in Health Care (IQWiG) in Germany, to use disease-
specific outcome measures within different therapeutic
areas. IQWiG’s position could be interpreted as meaning
that patient groups in which treatment is highly effective
relative to resources expended should not necessarily
take priority over groups where treatment outcomes for
resources used are more modest [38].
Summary
On the question of whether it is feasible to estimate a
monetary value of a QALY, the jury is still out: probably
the most that can be said is that, based on population
average values derived from survey research, there is as
yet no compelling evidence for moving the current
threshold either up or down. Although ours was merely
a feasibility study, it would be reasonable to say that the
NICE response to the work conducted in SVQ was one
of reassurance over this position.
Nevertheless, raising the threshold for some condi-
tions should not necessarily be ruled out on grounds of
affordability. Rarer and higher-valued (life-saving)
QALYs (such as for heroic, or even some routine, types
of surgery) could be paid for through having a lower
threshold for more common quality-of-life-enhancing
types of QALY. This is what we mean by both sides of
the threshold-level debate being right and wrong,
although such a move would require in-depth validation
of the results on QALY types displayed in Table 1.
While many members of the public appear to be open
to the possibility of using somewhat different QALY
weights for different groups of beneficiaries, we do not
yet have any secure evidence base for introducing such
a system. In England, this remains reflected in the
recently-revised social value judgment document pro-
duced by NICE, published after the submission of the
report of the SVQ project [39].
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